Climb Bio Valuation

Is CLYM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLYM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CLYM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLYM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLYM?

Key metric: As CLYM is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CLYM. This is calculated by dividing CLYM's market cap by their current book value.
What is CLYM's PB Ratio?
PB Ratio	0.9x
Book	US$218.78m
Market Cap	US$205.03m

CLYM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CLYM's PB Ratio compare to its peers?

The above table shows the PB ratio for CLYM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.6x
XBIT XBiotech	1.1x	n/a	US$208.2m
MGNX MacroGenics	1.7x	-23.9%	US$203.4m
INBX Inhibrx Biosciences	1.2x	n/a	US$203.8m
NGNE Neurogene	2.4x	-29.9%	US$301.0m
CLYM Climb Bio	0.9x	n/a	US$205.0m

Price-To-Book vs Peers: CLYM is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.6x).

Price to Book Ratio vs Industry

How does CLYM's PB Ratio compare vs other companies in the US Biotechs Industry?

59 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$554.58m
IMAB I-Mab	0.4x	1.8%	US$76.59m
ACET Adicet Bio	0.4x	6.7%	US$74.16m
MGX Metagenomi	0.3x	-23.2%	US$70.73m

59 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CLYM is good value based on its Price-To-Book Ratio (0.9x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is CLYM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLYM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CLYM's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

6.1%

14.8%